533
24224226014562118
Ces8507936014570127174
Urol10497936014578115180208
2022;12827936014562121178238261
26(1):15697936014561119152206230252
13–2818477936014561113174229288
PŘEHLEDOVÉ852207016974156235334409485586692777855
ČLÁNKY1746207016989162260360444533
36.850896013356112134
Sharma1008896013356116168203295348
P,137989601336069
Zargar‑Shoshtari1472896013362116151212264300330382442502545605640693729754
K,224989601336287
Caracciolo2360896013365118153206255302327387413473
JT,285789601334297113
et299489601335693
al.311089601335580102
Sarcopenia3237898013153103134181237297351409431479
as374089801315291
a3855898013152
predictor393189801316395146206228277313369401
of435689801316088
overall4469898013160108160191241263285
survival4778898013143100131184207256306328
after513089801315279117168199
cytoreductive850104801314999136191222273333389437472494542593
nephrectomy14671048013155107166224254305354389445533579
for2069104801312581113
metastatic22051048013186138171220259293342373395442
renal2671104801312879136184206
cell2900104801314595117139
carcinoma.3062104801314594125171192249306395443462
Urol3547104801316595151173
Oncol37441048013169127175230253
Semin4021104801314699187208265
Orig43091048013170101124182
Investig.4514104801311976123174214248269327346
2015;48831048013150100147191206
33(8):5112104801315099124175200217
339.e17–339.e23.8501198013154103153169221266309358407456506522574626679697
doi:10.1016/j.urolonc.2015.15711198013160118140157201249266312359407454491515533591622678701759818867886940992104010841101
01.26961198013154102114
011.28341198013154102142155
37.8501346013356108119
Psutka993134601335496155191242295
SP.13111346013351108117
Personalizing14531348013151102133174231290338360382425448505564
preoperative2041134801315789140198258312343393425447496548
risk261313480131285189134
stratification2771134801313772103153185207232259307357389411468526
and33211348013146104163
refining3508134801312880105132189211268327
patient38591348013157106138160213270302
selection4185134801313790112165214250272329387
for4596134801312582114
cytoreductive4734134801314596133189221272332389437473495544595
nephrectomy8501498013159112172230262313363399455544590
in1465149801312380
metastatic15691498013190143177226266300350382404453
renal2046149801313284142190213
cell22831498013149100122144
carcinoma.2451149801314999130177198256314404453472
Cancer.29471498013163112170219270301315
2020;32861498013154105155207225
126(17):3535149801315498149177224268297314
3912–3915.38731498013153103152196248297347395440456
doi:10.1002/cncr.32993.43541498013159117140157201248266312359414464504547605653685699753802853907956974
38.8511646013356112135
Ito1009164601333368127
H,11601646013377101
Shioi12841646013360120145205231
K,1538164601336691
Murakami16521646013395155190243294348439464
T,2139164601336177
et2239164601336197
al.2360164601335984106
C‑reactive2490164801316987120171219268304326376427
protein2942164801316698155187238260318
in3284164801312986
patients33951648013166116148171223281313354
with37741648013185108141199
advanced39971648013156116165215273321372432
metastatic44531648013197150183233272307356389411459
renal4936164801313990148197219
cell51791648013155106129150
carcinoma:850179801314999130177198256314403452469
Usefulness13431798013166104157185244266323376416456
in1823179801311977
identifying1924179801311978131189220242271323346403463
patients24111798013157107139161213271303345
most27801798013186144184219
likely302317980131194186137160208
to3255179801313086
benefit33651798013157111169222248274307
from3697179801312558114204
initial392517980131197698131153202224
nephrectomy.41731798013155108168226257309358394450540586599
BMC47961798013152136198
Cancer.50181798013159109166215266297311
2012;8501948013154105153197215
12(1):1089194801315498123171191208
337.13211948013154103151158
doi:10.1186/1471-2407-12-337.15041948013159117140157201248266312353399453490540587635684711757805860909936982102610561105115512031210
39.8502096013356110129
Sakai10022096013351104155208233
I,1259209601332245
Miyake13282096013385110162215266319
H,1671209601336891
Hinata1785209601336894154206242295
N,2103209601336992
Fujisawa22182096013350108133159201254334386
M.26282096013385109
Improved27612098013120108168200256305356417
survival3202209801313794125178201250300322
in3548209801311977
patients36492098013157107139161213271303345
with4018209801317698131189
metastatic42312098013187140173223262297346379401449
renal4704209801312980138187209
cell4937209801314696119141
carci‑5102209801314595126173194227
noma8502248013159117207256
undergoing11302248013156113173226257315373395453512
cytoreductive1667224801314697134190222274334391440476498547599
nephrectomy22902248013157110169228259311360396452542588
in2902224801312178
the3004224801313290143
era3171224801315182132
of3327224801315685
targeted3436224801313181112170223256307367
therapy.3827224801313290143174224284331345
Int4196224801312078110
J43302248013135
Clin4390224801316082103161
Oncol.45752248013171130179234258276
2014;48752248013151103151197214
19(4):5113224801315196124174199216
674–678.8502398013154103149205262312362382
doi:10.1007/s10147-013-0612-z.125623980131601181401572012482663123594144634925285736206687147637908468949399711028108211271172120212421262
40.8502546013356113134
Baum10072546013356108167258
YS,12872546013356107130
Patil14402546013354105140164189
D,1652254601336988
Huang17632546013367127179238299
JH,20852546013337108130
et2238254601335187
al.234825460133497496
Elevated2468254801314768121169218250300360
preoperative2851254801315788139198257311342391423444493544
neutrophil‑to‑lymphocyte34192548013155107164197228284344402423445477510565600623670760819877934983103410701121
ratio4563254801312978110132189
may47752548013186134180
be49792548013156110
asso‑5113254801314585124181216
ciated850269801314970118149199259
with1133269801317497129187
decreased13432698013156108157187238286325377437
overall18032698013154102153184233255276
survival2103269801313792123175198246295317
in2444269801311975
patients25432698013156105137159211268299340
with2907269801317497129187
metastatic31172698013186138171220259293342373395442
clear3583269801314566118166197
cell3803269801314595117138
renal3965269801312879136184206
cell4195269801314495117138
carcinoma4357269801314493124170191248306394443
undergoing48232698013154111170222253310367389446505
cytoreductive8502848013149100137193225277337394443479501550602
nephrectomy.14762848013159112172230262313363399455544591604
Asian21042848013165107128176234
J23622848013138
Urol.24242848013169100156179198
2016;26462848013153105153199217
3(1):2887284801315380127148164
20–25.30752848013154106164211264281
doi:10.1016/j.ajur.2015.33802848013160118140157201248266312359407454491515533585607664695709764816863908925
09.43292848013154107122
004.44752848013154109164182
41.8502996013356105122
Peyton9952996013355108158198256317
CC,13352996013360120144
Abel15022996013364126181207
EJ,1732299601335093114
Chipollini18692996013360120145206267293318343403428
J,2320299601333758
et2401299601335188
al.251229960133497497
The26332998013147107160
Value2817299801315299121178230
of3071299801315583
Neutrophil31782998013166119177210242298358416438460
to3662299801313086
Lymphocyte3772299801314587177237295353402453490541
Ratio43372998013152101133155213
in4573299801312077
Patients4674299801315199131153206263295336
Under‑50342998013165122182234266295
going8503148013160118140198257
Cytoreductive11313148013162104141197229281341398447483505554606
Nephrectomy17613148013170123183241272324373410466555601
with23863148013179102135193
Thrombectomy.26033148013151111142199288348402452488544633680693
Eur33203148013151106137
Urol34813148013169100156179
Focus.36843148013151107157214254273
2020;39813148013153105154206224
6(1):4229314801315481129149166
104–111.44193148013153100155212259299340352
doi:10.1016/j.47953148013160118140157202249266312360407454491515534
euf.2018.8503298013153111139155210261309356375
08.12493298013154108127
023.14003298013154103156174
42.8503446013356109132
Day10053446013380132182
D,1210344601338099
Kanjanapan13333446013366120180205257318370432485546
Y,1902344601336681
Kwan20073446013366143196256
E,2287344601336083
et2393344601336299
al.2515344601336085108
Benefit26473448013163116174227253279312
from2984344801313568125214
cytoreductive32233448013155106144200232283344401449485507557608
nephrectomy38563448013165119178237268319369405461551597
and44773448013157115174
the4675344801314199152
prognostic48513448013168100157217275333373407429478
role850359801313289112164
of1038359801315583
neutrophil‑to‑lymphocyte11453598013155108165198230286346405426448481514570604628676766825883941991104110791129
ratio2298359801312979111133190
in2512359801311976
patients26123598013157107139161213271302344
with2980359801317598131189
metastatic31933598013186139171221260295344376398446
renal3663359801312980138186208
cell3895359801314596118140
carcinoma.4059359801314595126172194251309398447466
Intern4549359801312077109159191249
Med48223598013182135195
J.5041359801313451
2016;51163598013150102149195213
46(11):8503748013154109137184225245262
1291–1297.1136374801315398150198247293338389439446
doi:10.1111/imj.13202.16063748013160118140157202249267313353394435467490579601619665710759810860878
43.8503896013356110132
Gu10053896013377138
L,1166389601335881
Ma12713896013394147
X,1441389601336993
Xie1557389601336994149
Y,1729389601336581
et1833389601336197
al.1954389601335984106
Pretreatment2085389801316192143177208260308340429483541572
Lymphocyte2681389801315698188248307365414465503554
to3259389801314096
Monocyte33793898013192150209267316367405456
Ratio38593898013161111143165223
is4106389801312968
an41983898013156114
Independent4336389801312987147200259313371431484541573
Prognos‑4933389801316292149209267325365396
tic850404801313456105
Factor9794048013159104153189245277
in1281404801313189
Metastatic13944048013194148181231271305355388410459
Clear1877404801317193146194226
Cell21274048013171122145167
Renal23184048013164118176225247
Cell25904048013171122145167
Carcinoma.27814048013171121152199221279338428477496
Clin3301404801317193115173
Genitourin34984048013177131190211245301360391414472
Cancer.39944048013171121179228279311325
2017;43434048013162114162206219
15(3):45874048013161106132183208225
e369–e377.48374048013161114166218275331384432485492
doi:10.1016/j.clgc.2016.8504198013160118140157202249267313360407454491515534582604663712731786837885931950
12.1824419801315499116
001.19654198013153108156168
44.8504346013356113135
Margulis10074346013384136170230288313337379
V,1408434601335772
Shariat15034346013349108160194219270304
SF,18304346013350101112
Rapoport19654346013354106167227288348383421
Y,2408434601335570
et2500434601335186
al.260943460133487395
Development27284348013166119166217239296355443495552583
of3334434801315481
Accurate34394348013159106151207238287318368
Models38304348013181138197249271309
for4162434801312480112
Individualized4297434801311975134155203225283339387408429472522581
Prediction4901434801315181131190211258294315372429
of850449801315987
Survival9614498013159116147200223272322344
After13294498013172100138189220
Cytoreductive15734498013171112149205237289349406455491513562614
Nephrectomy22114498013178131191250281332382418474563610
for2845449801313694126
Metastatic29954498013193146179229269303353385407455
Renal34744498013164117175224246
Cell37444498013170121144166
Carcinoma.39344498013170120151198220277336425474493
Eur44514498013159115146
Urol.46214498013177107164187205
2013;48504498013162114161206222
63(5):50964498013161112139189216233
947–952.8514648013154108156205258309359377
doi:10.1016/j.eururo.2012.1252464801316011814015720224926731336040745449251553458664467573376582183989494599310371055
11.2331464801315495107
040.24624648013154109164182
45.8504796013357111132
Corcoran10064796013372130166215274310363424
AT,14534796013376123139
Kaffenberger16164796013367122153186241302364420456517573608
SD,22484796013362135154
Clark2426479601337296149185236
PE,26864796013366119142
et28514796013363100
al.2975479601336186109
Hypoalbuminaemia31084798013178126188247297320379438527549607656709799821870
is4002479801313170
associated4097479801315898138197246268317349401461
with45834798013187110144202
mortality48104798013198157189226276299320354406
in5240479801313189
patients8504948013161111143165217275307349
undergoing12234948013158116176228260318376398456515
cytoreductive17624948013149100137193225277337394443479501550602
nephrectomy.23884948013159112172231262313363399455545591604
BJU3016494801315692160
Int.3200494801312481113132
2015;33564948013154105153198213
116(3):3593494801315394141169220244261
351–357.38784948013154103150199248298348355
doi:10.1111/bju.12897.42574948013160118140157202249267313353394435467528550607626672716767819869876
46.8505096013356114136
Lee10105096013348102158
H,1191509601336891
Kim1305509601335683173
YJ,1501509601335690111
Hwang16355096013368148201261322
EC,19805096013351113137
et2140509601335288
al.225150960133497497
Preoperative2372509801315182133192252306337387419441490542
cholesterol29385098013145102161184236276311361393449472
level3434509801312072121173195
as3653509801314686
a37635098013146
new38335098013155108186
independent4043509801311977136189248302360419472530561
predictive4628509801315789140200222270306328377429
factor5081509801312575124160216248
of850524801315886
survival960524801313894125177200249298320
in1304524801311977
patients14045248013157107139161213270302343
with1771524801317698131189
metastatic19845248013186139171221260294344376397445
renal2453524801312980138186208
cell2685524801314596118140
carcinoma2848524801314695126172194251309398447
treated3319524801313061113160192243303
with3646524801317597130188
cyto‑reductive3858524801314596133188222255306366423471507529578629
nephrectomy.45115248013155108167225256308357393448537583597
BMC51315248013152136198
Cancer.8505398013163112170219270301315
2017;11895398013154105153197210
17(1):1423539801315497121168189205
364.16525398013154106162180
doi:10.1186/s12885-017-3322-5.185653980131601181401572012482663123533994534915275716166677217728058629099539801029107811271180121012611278
47.8505546013357109121
Ishihara995554601333477138164225278314367
H,13865546013380104
Kondo15145546013368127189251312
T,1850554601336379
Yoshida19535546013368122165226252314367
K,2344554601336894
et24625546013363100
al.2586554601336187110
Evaluation27205548013160109159182240289322344403462
of3206554801316897
Preoperative3327554801316495147207268323354405438460510563
Aspartate39145548013173116176226258296346379430
Transaminase/Alanine4369554801316085135194234285374397455504545598638695718767826848906960
Transaminase850569801315175125182221271359380437486525577
Ratio14515698013152101132154211
as1686569801314685
an17955698013146103
Independent1922569801311976135188247300358417469526558
Predictive2503569801315282133192214262297319368419
Biomarker2946569801315173130219268299344396427
in3396569801311976
Patients3496569801315199131152204262293334
With38545698013186109142200
Metastatic40775698013182134167216256290339371392440
Renal45415698013151104161210231
Cell47965698013159109132153
Carcino‑49735698013158107138185206263321356
ma8505848013190139
Undergoing10135848013165122181234265323381403461520
Cytoreductive15575848013159100137193225276337394442478500549601
Nephrectomy:21825848013166119179237268320369405461551597616
A28225848013161
Propensity2907584801315181138198252310349370403454
Score3385584801314896152184236
Matching36455848013181130162209266288345404
Study.4073584801314879136196244257
Clin4354584801315981103160
Genitourin45385848013165119176198231287345376399456
Cancer.50185848013159109166215266297311
2017;8505998013154105153197210
15(5):1084599801315398124175201218
598–604.13265998013154102155212269323378396
doi:10.1016/j.clgc.2017.17465998013159118140157201248266312359407454491515533581603663711730785837884928935
04.27055998013154109127
011.28565998013154101142154
48.8506146013356114137
Laukhtina10106146013348102161212274309334394446
E,1479614601335073
Pradere1575614601335589142203258293348
B,1946614601335578
D`Andrea2047614601336998154215276311365418
D,2488614601336988
et2599614601335288
al.271061460133497597
Association28316148013160102142200249271319351373430488
of3343614801315583
preoperative3450614801315789140199259313344393425447496548
serum4022614801313790121179268
De43146148013167120
Ritis4458614801315274108129168
ratio4650614801312978110132190
with4864614801317598131189
onco‑50776148013154112161217252
logical850629801312381141163211261283
outcomes11576298013155113146192248338391431
in1612629801311977
patients17136298013157107139161213271303344
treated2081629801313162114162194245305
with2410629801317698132189
cytoreductive2624629801314596133189221272332389438474496545597
nephrectomy32456298013155108168226257309358394450540586
for3855629801312582114
metastatic39936298013186139172222262296346378400448
renal4465629801312980138187209
cell4698629801314596118140
carcinoma.4862629801314695126173195252310400449467
Urol8506448013169100156179
Oncol10536448013174133182238261
Semin13386448013151104193215272
Orig16346448013174107129188
Investig.1846644801312481129180221255277336355
2020;22256448013154105155206225
38(12):24746448013153106134181226252268
936.e7–936.e14.27666448013154104156175228277325378427480499551596642660
doi:10.1016/j.urolonc.2020.34506448013160118140157201249266312359407454491515533591622678701759818867886940992104110931111
08.45856448013154108127
013.47366448013154101146164
49.8506596013356110129
Culp10036596013362120145207
SH,12336596013352123146
Schellhammer14026596013353102162217243268328380471563618653
PF,20796596013356108120
Williams22226596013391118143168192245336378
MB.26246596013386146168
Might28176598013184106165223255
Men30966598013183136194
Diagnosed3314659801317092140200258316356409469
with38076598013178100134192
Metastatic40236598013183137170219259294343375397446
Prostate4493659801315384140180215264296347
Cancer48646598013161111169217268300
Be‑51886598013153107142
nefit8506748013159111137163196
fromDefinitive1070674801312558114203294347372399456477510532581632
Treatment1726674801314772123171202291344402433
of2183674801315482
the2289674801313088141
Primary2453674801315282104192241272323
Tumor?2800674801314797185243275307
A31316748013160
SEER‑Based3215674801314795145198230286336375428488
Study.3726674801314878136195243256
Eur40056748013148103134
Urol.4162674801316596152175193
2014;43786748013150101149195211
65(6):46136748013149100126175201218
1058–1066.4855674801314996147199255300347401455474
doi:10.1016/j.eururo.2013.850689801316011814015720224926731336040745449151553458664467573376582183989494599310371055
11.1929689801315495107
012.20606898013154102146164
50.8507046013356111133
McIntosh10067046013385134159219254313356416
AG,14457046013364132155
Umbreit16247046013367158220255310335371
EC,20187046013351113137
Holland21787046013368129155180232292354
LC,25557046013349109133
et2711704601335288
al.282270460133507597
Optimizing29437048013170131163185274296339362419478
patient34457048013157107139161214272303
selection3772704801313891113166215251273331389
for4185704801312582114
cytoreductive4323704801314696134189221273333390438474496545597
nephrec‑49447048013155108168226257309358385
tomy850719801313490180226
based11007198013158108148201261
on13857198013157115
outcomes15247198013157115148194250340393433
in1981719801312179
the2084719801313189143
contemporary22517198013146102161193244333392451483533565616
era2892719801315182132
of3048719801315685
systemic3157719801313988128163214303325373
therapy.3554719801313290143174224284331345
Cancer.39237198013160110168216267298312
2020;42607198013151103152204222
126(17):4506719801315196147175222266295311
3950–3960.48417198013152102154205263312362416470488
doi:10.1002/cncr.32991.8507348013160118140157202249267313360415464504547605654685699753802854907956968